Patients in the immune-suppressed group showed the worst recurrence-free survival, increased expression of IL-11, TGFB1, and TGFB2, and enrichment of tumor-infiltrating Treg signatures (p < 0.01), while immune-activated PCs (14.9–24.3%) might benefit from anti-PD-1/PD-L1 therapy, as to their higher expression of immune checkpoint (PD-L1 and CTLA-4) and chemokine genes (CXCL9 and CXCL10). This evidence concerns the gene CD274 and neoplasm.